India's Sun Pharma gets FDA nod for generic Cerebyx
MUMBAI, March 19 (Reuters) - India's Sun Pharmaceutical Industries Ltd (SUN.BO) said on Wednesday it had received approval from the U.S. Food and Drug Administration for fosphenytoin sodium injection.
The drug, a generic variant of Pfizer Inc's (PFE.N) Cerebyx, is indicated in the control of certain types of convulsions and for seizures during neurosurgery, Sun said in a statement.
The drug has annual sales of about $15 million, it said. (Reporting by Rina Chandran; Editing by Mark Williams)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
